| Clinical Trial Stage Projects | Dr. Kristen A Johnson | Evaluation of the Safety and Tolerability of KA34 in a Phase 1, Double-Blind, Dose Escalation Trial in Patients with Knee Osteoarthritis |
$8,447,523 |
| Late Stage Preclinical Projects | Peter G Schultz | Development of a Chondrogenic Drug Candidate Targeting Resident Mesenchymal Stem Cells for the Treatment of Osteoarthritis |
$1,667,832 |
| Preclinical Development Awards | Peter G Schultz | Development of a Chondrogenic Drug Candidate Targeting Cartilage-residing Mesenchymal Stem Cells for the Treatment of Osteoarthritis |
$2,306,703 |
